Skip to main content
Premium Trial:

Request an Annual Quote

The Effectiveness of Comparing Effectiveness

Pharmalot's Ed Silverman discusses the results of the National Pharmaceutical Council's recent survey on comparative effectiveness research and why, according to the data, the concept doesn't appear to be a "potent" one. In surveying 111 individuals at federal agencies, in consumer and trade groups, and in academia, among other places, the NPC — a pharma-supported policy research organization — found that nearly 60 percent considered themselves "very familiar" with comparative effectiveness research, though only 30 percent indicated they felt that it would "lead to moderate improvements in health care decision-making in the next year," Silverman says. In addition, he says, the NPC found that among its 111 participants, 85 percent indicated they felt that comparative effectiveness research "led to little or no improvement for health care decision-making in the past year," 11 percent said it had "led to moderate improvements," and 30 percent indicated they thought it "would lead to moderate improvements in health care decision-making in the next year."

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.